Skip to main content
Novartis Home

Language & Country Selector for Desktop

language-selector-globe Global | en

Choose Location

  • International
  • Americas
  • Asia Pacific
  • Europe
  • Middle East & Africa
Global | en
Sandoz | en
Novartis Foundation | en
Argentina | es
Brazil | pt
Canada | en
Canada | fr
Central America | es
Colombia | es
Mexico | es
United States | en
Venezuela | es
Australia | en
Bangladesh | en
Hong Kong S.A.R. | zh
India | en
Indonesia | en
Japan | ja
Korea | ko
Mainland China | zh
Malaysia | en
Pakistan | en
Philippines | en
Singapore | en
Taiwan | zh
Austria | de
Belgium | fr
Belgium | nl
Bulgaria | bg
Czech Republic | cs
Czech Republic | en
Denmark | da
Estonia | et
Finland | fi
France | fr
Germany | de
Greece | el
Hungary | hu
Ireland | en
Italy | it
Latvia | lv
Lithuania | lt
Netherlands | nl
Norway | no
Poland | pl
Portugal | pt
Romania | ro
Russia | ru
Serbia | sr
Slovakia | sk
Spain | es
Sweden | sv
Switzerland | de
Switzerland | fr
United Kingdom | en
Egypt | en
Israel | he
South Africa | en
Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Global

Choose Location

International Americas Asia Pacific Europe Middle East & Africa
Argentina | es
Australia | en
Austria | de
Bangladesh | en
Belgium | fr
Belgium | nl
Brazil | pt
Bulgaria | bg
Canada | en
Canada | fr
Central America | es
Colombia | es
Czech Republic | cs
Czech Republic | en
Denmark | da
Egypt | en
Estonia | et
Finland | fi
France | fr
Germany | de
Greece | el
Hong Kong S.A.R. | zh
Hungary | hu
India | en
Indonesia | en
Ireland | en
Israel | he
Italy | it
Japan | ja
Korea | ko
Latvia | lv
Lithuania | lt
Mainland China | zh
Malaysia | en
Mexico | es
Netherlands | nl
Norway | no
Global | en
Sandoz | en
Novartis Foundation | en
Pakistan | en
Philippines | en
Poland | pl
Portugal | pt
Romania | ro
Russia | ru
Serbia | sr
Singapore | en
Slovakia | sk
South Africa | en
Spain | es
Sweden | sv
Switzerland | de
Switzerland | fr
Taiwan | zh
Turkey | tr
United Kingdom | en
United States | en
Venezuela | es
    • About 
      • Board of Directors 
        • Joerg Reinhardt 
        • Simon Moroney 
        • Nancy C. Andrews 
        • Ton Buechner 
        • Patrice Bula 
        • Elizabeth (Liz) Doherty 
        • Ana de Pro Gonzalo 
        • Bridgette Heller 
        • Daniel Hochstrasser 
        • Frans van Houten 
        • Charles L. Sawyers 
        • William T. Winters 
        • John D. Young 
        • Charlotte Pamer-Wieser 
      • Executive Committee 
        • Vasant (Vas) Narasimhan 
        • Shreeram Aradhye 
        • Victor Bulto 
        • Aharon (Ronny) Gal 
        • Karen L. Hale 
        • Harry Kirsch 
        • Rob Kowalski 
        • Steffen Lang 
        • Fiona Marshall 
        • Klaus Moosmayer 
        • Marie-France Tschudin 
        • Lutz Hegemann 
        • Kees Roks 
        • Richard Saynor 
        • Michael Willi 
      • Strategy 
        • People and Culture 
        • Data and Digital 
      • Products 
      • Innovative Medicines 
      • Therapeutic areas 
        • Cancer 
        • Hematology 
      • Sandoz 
      • Diversity, Equity & Inclusion 
        • Equity 
        • Diversity, Equity & Inclusion Governance and Community 
        • Inclusivity 
        • Parental Leave 
        • Society 
      • Manufacturing 
      • Quality 
        • Audit program 
        • Novartis Quality Management System (QMS) 
        • Product and patient safety training 
        • Regulatory inspections 
        • Product recalls 
        • Third-party suppliers 
      • Awards and Recognition 
      Male scientist in lab

      About

      Learn about how Novartis is organized and our strategy, vision and mission. Meet our people and read about our commitments to diversity, equity and inclusion. Explore our history which goes back more than 250 years.

    • Patients and Caregivers 
      • Novartis Commitment to Patients and Caregivers 
      • Diseases 
      • Patient Organization Funding 
      • Stories: Patients Perspectives 
      Couple holding hands

      Patients and Caregivers

      Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.

    • Healthcare Professionals 
      • Medical Congresses and Events 
        • Abstract summaries for EULAR 
        • Abstract summaries for ACR 
        • ASCO Annual Meeting 
      • Products 
      • Novartis Pipeline 
      • Managed Access Programs 
        • Novartis Gene Therapies Managed Access Program 
      • Novartis External Funding 
      • Healthcare Professional Resources by Country 
      • Investigator-Initiated Trials / Studies 
      • Transparency and Disclosure 
      • Novartis Medical Information 
        • Submit medical enquiry 
      Doctor

      Healthcare Professionals

      Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information.

    • Research & Development 
      • Novartis Institutes for BioMedical Research 
        • Collaborations 
        • NIBR Global Scholars Program 
      • Technology Platforms 
        • Radioligand Therapy 
        • Gene Therapy 
        • Cell Therapy 
      • Research Disease Areas 
        • Cardiovascular and metabolic disease research at Novartis 
        • DAx: exploratory disease research at Novartis 
        • Global Health disease area research at Novartis 
        • Immunology disease research at Novartis 
        • Neuroscience research at Novartis 
        • Oncology research at Novartis 
        • Ophthalmology research at Novartis 
      • Research Locations 
      • Novartis Pipeline 
      • Translational Medicine 
      • Research Collaborations 
      • Open Source Science 
      • Stories from our Labs 
      Scientists conducting innovative research experiments

      Research & Development

      Discover how Novartis turns breakthrough science into transformative, high-value treatments. Learn about our innovation engine, the Novartis Institutes for BioMedical Research (NIBR) and explore our research areas, technology platforms and pipeline.
       

    • ESG 
      • Access 
        • Creating sustainable business models 
        • Value-Based Pricing 
        • Sub-Saharan Africa 
        • Donations 
        • Novartis Access Principles 
        • Novartis Oncology Access 
        • Patents and Licensing 
      • Ethics, Risk and Compliance 
        • Ethical Behavior 
        • Compliance 
        • Human Rights 
        • Learning and Engagement 
        • Risk management 
      • Environmental Sustainability 
        • Climate 
        • Waste 
        • Water 
      • Global Health 
        • Anti-Microbial Resistance (AMR) 
        • Avoidable Blindness 
        • Chagas Disease 
        • Leprosy 
        • Malaria 
        • Sickle Cell Disease (SCD) 
        • Novartis Foundation 
      • Diversity, Equity & Inclusion 
      • Reporting 
        • ESG Rating Performance 
        • Codes, Policies and Guidelines 
        • Materiality Assessment 
        • Transparency and Disclosure 
        • Targets 
        • Positions 
      • ESG Index 
      Young patients waiting outside an hospital in Rwanda

      Environmental, Social and Governance

      Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. Explore the Novartis in Society Integrated Report.

    • Investors 
      • Event Calendar 
      • Financial Data 
        • Novartis Annual Results 
        • Novartis Quarterly Results 
        • Novartis SEC Filings 
        • Product Sales 
        • Fixed-Income Securities 
        • Expected Currency Impact 
      • Share Data & Analysis 
        • Share Monitor 
        • Dividend Information 
        • Share Ownership 
        • Share Overview 
        • Return On Investment Calculator 
      • Shareholder Information 
        • General Meetings 
        • American Depository Receipts (ADR) 
        • Share Buy-Back 
        • Frequently Asked Questions 
      • Company Overview 
        • Corporate Governance 
      • Novartis Annual Reporting Suite 
        • Reporting Archive 
        • Publications Order Form 
      • ESG 
      Hands marking a test tube

      Investors

      Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting.

    • News 
      • News Archive  
      • Media Library  
      • Stories 
      • Subscribe 
      People at the table with screens

      News

      Information for journalists including media releases, statements, stories, multimedia resources and more.

    • Careers 
      • Career Search 
      • Benefits & Rewards 
      • Career Programs 
        • Community Exploration & Learning Lab (CELL) 
        • Postdoc Program 
      • Early Careers 
        • Careers in Data, Digital & Information Technology (IT) 
        • Careers in Manufacturing and Supply 
        • US NIBR Internship Programs 
      • Personal Growth 
      • Wellbeing 
      Close-up portrait of a scientist in Cambridge, USA

      Careers

      Novartis is hiring! Find open positions, learn more about our strategy and culture, and apply today.

    • Clinical Trials 
      doctor taking the blood pressure of her patient

      Clinical Trials

      Find recruiting clinical trials and learn more about how to participate or work with Novartis on clinical studies. Read about our clinical trials transparency initiatives.

    • Partnering 
      Business people working in a dark room

      Partnering

      Learn about our approach to partnering which combines capabilities, collaboration and culture.

    • Supplier Portal 
      Group of business people in a meeting area

      Supplier Portal

      Practical information and resources for suppliers around the world.

    • Report side effects 
    • Contacts 
      Office Cubicle

      Contacts

      Get in touch.

    engineers walking in packaging facility big_0

    Home

    Welcome to Novartis where we are reimagining medicine to improve and extend people’s lives.

Placeholder Image

Cell and Gene Therapy

Tags Archive Navigation
  • All
  • Careers
  • Featured News
  • In the News
  • Media Releases
  • Story
icon
  • Media Release
    Jun 17, 2022
    Novartis announces Nature Medicine publication of Zolgensma data demonstrating age-appropriate milestones when treating children with SMA presymptomatically
  • Media Release
    Jun 12, 2022
    Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
  • Media Release
    May 28, 2022
    FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
  • Story
    May 27, 2022
    How Emily’s act of bravery inspired a wave of continued innovation
  • Media Release
    May 04, 2022
    Novartis Kymriah® receives EC approval as first CAR-T cell therapy for adults with relapsed or refractory follicular lymphoma
  • Media Release
    Mar 25, 2022
    Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
  • Media Release
    Mar 10, 2022
    Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy
  • Media Release
    Dec 22, 2021
    Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness
  • Media Release
    Dec 13, 2021
    Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
  • Media Release
    Aug 24, 2021
    Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma
  • Media Release
    Sep 21, 2021
    Novartis übernimmt Arctos Medical und erweitert damit ihr Optogenetik-Portfolio, um Patientinnen und Patienten mit einem schwerem Verlust des Sehvermögens Gentherapien anbieten zu können
  • Media Release
    Sep 21, 2021
    Novartis acquiert Arctos Medical, élargissant ainsi son portefeuille d’optogénétique afin de proposer des thérapies géniques aux patients souffrant d’une sévère perte de la vision

Pagination

  • 1
  • 2
  • 3
  • › Next page

Novartis

Navigate Novartis
  • Patients and Caregivers
  • Healthcare Professionals
  • Researchers
  • Job Seekers
  • Journalists
  • Investors
  • Partners
  • Suppliers
Topics
  • Clinical Trials
  • ESG
  • SpeakUp
Explore
  • Novartis Pipeline
  • Products
  • Therapeutic areas
  • Diseases
  • Stories
  • Locations
Novartis companies
  • Sandoz
  • Advanced Accelerator Applications
  • Gyroscope Therapeutics
Footer Bottom
© 2023 Novartis AG
  • Terms of Use
  • Privacy
  • Contacts
  • Cookie Settings
  • Site Map
  • Web Accessibility
  • Open Source
Novartis Site Directory
This site is intended for a global audience